Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.

Tytuł:
Predicting Venous Thromboembolic Events in Patients with Coronavirus Disease 2019 Requiring Hospitalization: an Observational Retrospective Study by the COVIDIC Initiative in a Swiss University Hospital.
Autorzy:
Kampouri E; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Filippidis P; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Viala B; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Méan M; Division of Internal Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Pantet O; Service of Intensive Care, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Desgranges F; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Tschopp J; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Regina J; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Karachalias E; Starling Bank Limited, London, UK.
Bianchi C; Division of Internal Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Zermatten MG; Service of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Jaton K; Institute of Microbiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Switzerland.
Qanadli SD; Cardiothoracic and Vascular Division, Department of Diagnostic and Interventional Radiology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Bart PA; Division of Internal Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Pagani JL; Service of Intensive Care, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Guery B; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Alberio L; Service of Hematology and Central Hematology Laboratory, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Papadimitriou-Olivgeris M; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Service of Hospital Preventive Medicine, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
RegCOVID Research Group; Service of Infectious Diseases, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Źródło:
BioMed research international [Biomed Res Int] 2020 Nov 06; Vol. 2020, pp. 9126148. Date of Electronic Publication: 2020 Nov 06 (Print Publication: 2020).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: New York, NY : Hindawi Pub. Co.
MeSH Terms:
COVID-19/*blood
Venous Thromboembolism/*virology
Aged ; Aged, 80 and over ; Antifibrinolytic Agents/therapeutic use ; COVID-19/epidemiology ; COVID-19/pathology ; Female ; Fibrin Fibrinogen Degradation Products/metabolism ; Humans ; Incidence ; Male ; Middle Aged ; Multivariate Analysis ; Pulmonary Embolism/drug therapy ; Pulmonary Embolism/epidemiology ; Pulmonary Embolism/virology ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; Switzerland/epidemiology ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/epidemiology ; Venous Thromboembolism/prevention & control ; Venous Thrombosis/drug therapy ; Venous Thrombosis/epidemiology ; Venous Thrombosis/prevention & control ; Venous Thrombosis/virology
References:
Euro Surveill. 2020 Jan;25(3):. (PMID: 31992387)
J Thromb Haemost. 2020 Apr;18(4):844-847. (PMID: 32073213)
Int J Epidemiol. 2011 Jun;40(3):819-27. (PMID: 21324940)
J Thromb Haemost. 2018 Feb;16(2):231-241. (PMID: 29193703)
Rev Med Suisse. 2020 May 6;16(692):917-923. (PMID: 32374537)
Ann Intern Med. 2020 Aug 18;173(4):268-277. (PMID: 32374815)
Thromb Res. 2020 Dec;196:222-226. (PMID: 32916564)
J Clin Med. 2020 Aug 03;9(8):. (PMID: 32756383)
Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16. (PMID: 12814980)
Thromb Res. 2020 Jul;191:145-147. (PMID: 32291094)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. (PMID: 32172226)
Respir Med Case Rep. 2019 Jun 14;28:100884. (PMID: 31245274)
Blood. 2019 Feb 28;133(9):906-918. (PMID: 30642917)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
J Thromb Haemost. 2020 Jun;18(6):1421-1424. (PMID: 32271988)
J Thromb Haemost. 2020 Jul;18(7):1743-1746. (PMID: 32320517)
Clin Infect Dis. 2011 Jan 15;52(2):e14-7. (PMID: 21288835)
Thromb Res. 2020 Nov;195:95-99. (PMID: 32682004)
Intensive Care Med. 2020 Jun;46(6):1089-1098. (PMID: 32367170)
Br J Haematol. 2019 Sep;186(5):792-793. (PMID: 31168834)
Thromb Res. 2020 Jul;191:9-14. (PMID: 32353746)
Eur Heart J. 2019 Nov 1;40(42):3453-3455. (PMID: 31697840)
J Thromb Thrombolysis. 2020 Apr 3;:. (PMID: 32246317)
J Thromb Haemost. 2020 Aug;18(8):1995-2002. (PMID: 32369666)
Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264)
Front Immunol. 2020 May 01;11:827. (PMID: 32425950)
JAMA Intern Med. 2020 Jul 1;180(7):934-943. (PMID: 32167524)
Circulation. 2012 May 1;125(17):2092-9. (PMID: 22474264)
Radiology. 2020 Jun;295(3):715-721. (PMID: 32053470)
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342. (PMID: 32202240)
Substance Nomenclature:
0 (Antifibrinolytic Agents)
0 (Fibrin Fibrinogen Degradation Products)
0 (fibrin fragment D)
Entry Date(s):
Date Created: 20201118 Date Completed: 20201204 Latest Revision: 20220418
Update Code:
20240105
PubMed Central ID:
PMC7656238
DOI:
10.1155/2020/9126148
PMID:
33204727
Czasopismo naukowe
Background: Coronavirus disease 2019 (COVID-19) can result in profound changes in blood coagulation. The aim of the study was to determine the incidence and predictors of venous thromboembolic events (VTE) among patients with COVID-19 requiring hospital admission. Subjects and Methods . We performed a retrospective study at the Lausanne University Hospital with patients admitted because of COVID-19 from February 28 to April 30, 2020.
Results: Among 443 patients with COVID-19, VTE was diagnosed in 41 patients (9.3%; 27 pulmonary embolisms, 12 deep vein thrombosis, one pulmonary embolism and deep vein thrombosis, one portal vein thrombosis). VTE was diagnosed already upon admission in 14 (34.1%) patients and 27 (65.9%) during hospital stay (18 in ICU and nine in wards outside the ICU). Multivariate analysis revealed D-dimer value > 3,120 ng/ml ( P < 0.001; OR 15.8, 95% CI 4.7-52.9) and duration of 8 days or more from COVID-19 symptoms onset to presentation ( P 0.020; OR 4.8, 95% CI 1.3-18.3) to be independently associated with VTE upon admission. D-dimer value ≥ 3,000 ng/l combined with a Wells score for PE ≥ 2 was highly specific (sensitivity 57.1%, specificity 91.6%) in detecting VTE upon admission. Development of VTE during hospitalization was independently associated with D-dimer value > 5,611 ng/ml ( P < 0.001; OR 6.3, 95% CI 2.4-16.2) and mechanical ventilation ( P < 0.001; OR 5.9, 95% CI 2.3-15.1).
Conclusions: VTE seems to be a common COVID-19 complication upon admission and during hospitalization, especially in ICU. The combination of Wells ≥ 2 score and D - dimer ≥ 3,000 ng/l is a good predictor of VTE at admission.
Competing Interests: All authors state that they have no conflict of interest to report.
(Copyright © 2020 Eleftheria Kampouri et al.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies